Skip to main content
Log in

The evolving role of adiponectin as an additive biomarker in HFrEF

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

Heart failure (HF) is a growing health problem. Despite improved management and outcome, the number of patients with HF is expected to keep rising in the following years. In recent research, adiponectin was shown to exert beneficial effects in the cardiovascular system, but the protein was also implicated in the development and progression of HF. The objective of this review is to provide an overview of current knowledge on the role of adiponectin in HF with reduced ejection fraction. We discuss the cardioprotective and (anti-) inflammatory actions of adiponectin and its potential use in clinical diagnosis and prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Stafford R, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J, American Heart Association Statistics C, Stroke Statistics S (2010) Executive summary: heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation 121(7):948–954. doi:10.1161/CIRCULATIONAHA.109.192666

    Article  PubMed  Google Scholar 

  2. Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, Meverden RA, Roger VL (2006) Systolic and diastolic heart failure in the community. JAMA 296(18):2209–2216. doi:10.1001/jama.296.18.2209

    Article  CAS  PubMed  Google Scholar 

  3. Bui AL, Horwich TB, Fonarow GC (2011) Epidemiology and risk profile of heart failure. Nat Rev Cardiol 8(1):30–41. doi:10.1038/nrcardio.2010.165

    Article  PubMed  Google Scholar 

  4. Warriner D, Sheridan P, Lawford P (2015) Heart failure: not a single organ disease but a multisystem syndrome. Br J Hosp Med 76(6):330–336. doi:10.12968/hmed.2015.76.6.330

    Article  Google Scholar 

  5. Joosten MM, Joshipura KJ, Pai JK, Bertoia ML, Rimm EB, Mittleman MA, Mukamal KJ (2013) Total adiponectin and risk of symptomatic lower extremity peripheral artery disease in men. Arterioscler Thromb Vasc Biol 33(5):1092–1097. doi:10.1161/ATVBAHA.112.301089

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Sook Lee E, Park SS, Kim E, Sook Yoon Y, Ahn HY, Park CY, Ho Yun Y, Woo OhS (2013) Association between adiponectin levels and coronary heart disease and mortality: a systematic review and meta-analysis. Int J Epidemiol 42(4):1029–1039. doi:10.1093/ije/dyt087

    Article  PubMed  Google Scholar 

  7. Shibata R, Ouchi N, Murohara T (2009) Adiponectin and cardiovascular disease. Circ J 73(4):608–614

    Article  CAS  PubMed  Google Scholar 

  8. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y (2000) Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102(11):1296–1301

    Article  CAS  PubMed  Google Scholar 

  9. Ouedraogo R, Wu X, Xu SQ, Fuchsel L, Motoshima H, Mahadev K, Hough K, Scalia R, Goldstein BJ (2006) Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway. Diabetes 55(6):1840–1846. doi:10.2337/db05-1174

    Article  CAS  PubMed  Google Scholar 

  10. Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA, Lopez BL, Koch W, Chan L, Goldstein BJ, Ma XL (2007) Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 115(11):1408–1416. doi:10.1161/CIRCULATIONAHA.106.666941

    Article  CAS  PubMed  Google Scholar 

  11. Frystyk J, Berne C, Berglund L, Jensevik K, Flyvbjerg A, Zethelius B (2007) Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab 92(2):571–576. doi:10.1210/jc.2006-1067

    Article  CAS  PubMed  Google Scholar 

  12. Haugen E, Furukawa Y, Isic A, Fu M (2008) Increased adiponectin level in parallel with increased NT-pro BNP in patients with severe heart failure in the elderly: a hospital cohort study. Int J Cardiol 125(2):216–219. doi:10.1016/j.ijcard.2007.12.002

    Article  PubMed  Google Scholar 

  13. Nakamura T, Funayama H, Kubo N, Yasu T, Kawakami M, Saito M, Momomura S, Ishikawa SE (2006) Association of hyperadiponectinemia with severity of ventricular dysfunction in congestive heart failure. Circ J 70(12):1557–1562

    Article  PubMed  Google Scholar 

  14. Sokhanvar S, Sheykhi M, Mazlomzade S, Taran L, Golmohammadi Z (2013) The relationship between serum adiponectin and prognosis in patients with heart failure. Bratisl Lek Listy 114(8):455–459

    CAS  PubMed  Google Scholar 

  15. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270(45):26746–26749

    Article  CAS  PubMed  Google Scholar 

  16. Shapiro L, Scherer PE (1998) The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol 8(6):335–338

    Article  CAS  PubMed  Google Scholar 

  17. Fang X, Sweeney G (2006) Mechanisms regulating energy metabolism by adiponectin in obesity and diabetes. Biochem Soc Trans 34(Pt 5):798–801. doi:10.1042/BST0340798

    Article  CAS  PubMed  Google Scholar 

  18. Yamauchi T, Kadowaki T (2008) Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes 32(Suppl 7):S13–S18. doi:10.1038/ijo.2008.233

    Article  CAS  Google Scholar 

  19. Tsao TS, Tomas E, Murrey HE, Hug C, Lee DH, Ruderman NB, Heuser JE, Lodish HF (2003) Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. J Biol Chem 278(50):50810–50817. doi:10.1074/jbc.M309469200

    Article  CAS  PubMed  Google Scholar 

  20. Waki H, Yamauchi T, Kamon J, Kita S, Ito Y, Hada Y, Uchida S, Tsuchida A, Takekawa S, Kadowaki T (2005) Generation of globular fragment of adiponectin by leukocyte elastase secreted by monocytic cell line THP-1. Endocrinology 146(2):790–796. doi:10.1210/en.2004-1096

    Article  CAS  PubMed  Google Scholar 

  21. Aso Y, Yamamoto R, Wakabayashi S, Uchida T, Takayanagi K, Takebayashi K, Okuno T, Inoue T, Node K, Tobe T, Inukai T, Nakano Y (2006) Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 55(7):1954–1960. doi:10.2337/db05-1525

    Article  CAS  PubMed  Google Scholar 

  22. Fisher FM, Trujillo ME, Hanif W, Barnett AH, McTernan PG, Scherer PE, Kumar S (2005) Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males. Diabetologia 48(6):1084–1087. doi:10.1007/s00125-005-1758-7

    Article  CAS  PubMed  Google Scholar 

  23. Nanayakkara G, Kariharan T, Wang L, Zhong J, Amin R (2012) The cardio-protective signaling and mechanisms of adiponectin. Am J Cardiovasc Dis 2(4):253–266

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, Scherer PE (2004) Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279(13):12152–12162. doi:10.1074/jbc.M311113200

    Article  CAS  PubMed  Google Scholar 

  25. Heidemann C, Sun Q, van Dam RM, Meigs JB, Zhang C, Tworoger SS, Mantzoros CS, Hu FB (2008) Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann Intern Med 149(5):307–316

    Article  PubMed  PubMed Central  Google Scholar 

  26. Combs TP, Berg AH, Rajala MW, Klebanov S, Iyengar P, Jimenez-Chillaron JC, Patti ME, Klein SL, Weinstein RS, Scherer PE (2003) Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes 52(2):268–276

    Article  CAS  PubMed  Google Scholar 

  27. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y (2002) Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51(9):2734–2741

    Article  CAS  PubMed  Google Scholar 

  28. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G (2003) Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 52(7):1779–1785

    Article  CAS  PubMed  Google Scholar 

  29. Berner HS, Lyngstadaas SP, Spahr A, Monjo M, Thommesen L, Drevon CA, Syversen U, Reseland JE (2004) Adiponectin and its receptors are expressed in bone-forming cells. Bone 35(4):842–849. doi:10.1016/j.bone.2004.06.008

    Article  CAS  PubMed  Google Scholar 

  30. Delaigle AM, Jonas JC, Bauche IB, Cornu O, Brichard SM (2004) Induction of adiponectin in skeletal muscle by inflammatory cytokines: in vivo and in vitro studies. Endocrinology 145(12):5589–5597. doi:10.1210/en.2004-0503

    Article  CAS  PubMed  Google Scholar 

  31. Krause MP, Liu Y, Vu V, Chan L, Xu A, Riddell MC, Sweeney G, Hawke TJ (2008) Adiponectin is expressed by skeletal muscle fibers and influences muscle phenotype and function. Am J Physiol Cell Physiol 295(1):C203–C212. doi:10.1152/ajpcell.00030.2008

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Kadowaki T, Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocr Rev 26(3):439–451. doi:10.1210/er.2005-0005

    Article  CAS  PubMed  Google Scholar 

  33. Ouchi N, Walsh K (2007) Adiponectin as an anti-inflammatory factor. Clin Chim Acta 380(1–2):24–30. doi:10.1016/j.cca.2007.01.026

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Shinmura K (2010) Is adiponectin a bystander or a mediator in heart failure? the tangled thread of a good-natured adipokine in aging and cardiovascular disease. Heart Fail Rev 15(5):457–466. doi:10.1007/s10741-010-9159-5

    Article  CAS  PubMed  Google Scholar 

  35. Tsubakio-Yamamoto K, Matsuura F, Koseki M, Oku H, Sandoval JC, Inagaki M, Nakatani K, Nakaoka H, Kawase R, Yuasa-Kawase M, Masuda D, Ohama T, Maeda N, Nakagawa-Toyama Y, Ishigami M, Nishida M, Kihara S, Shimomura I, Yamashita S (2008) Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages. Biochem Biophys Res Commun 375(3):390–394. doi:10.1016/j.bbrc.2008.08.009

    Article  CAS  PubMed  Google Scholar 

  36. Karbowska J, Kochan Z (2006) Role of adiponectin in the regulation of carbohydrate and lipid metabolism. J Physiol Pharmacol 57(Suppl 6):103–113

    PubMed  Google Scholar 

  37. Shibata R, Skurk C, Ouchi N, Galasso G, Kondo K, Ohashi T, Shimano M, Kihara S, Murohara T, Walsh K (2008) Adiponectin promotes endothelial progenitor cell number and function. FEBS Lett 582(11):1607–1612. doi:10.1016/j.febslet.2008.04.006

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423(6941):762–769. doi:10.1038/nature01705

    Article  CAS  PubMed  Google Scholar 

  39. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada-Iwabu M, Kawamoto S, Kubota N, Kubota T, Ito Y, Kamon J, Tsuchida A, Kumagai K, Kozono H, Hada Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Awazawa M, Takamoto I, Froguel P, Hara K, Tobe K, Nagai R, Ueki K, Kadowaki T (2007) Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13(3):332–339. doi:10.1038/nm1557

    Article  CAS  PubMed  Google Scholar 

  40. Yamauchi T, Iwabu M, Okada-Iwabu M, Kadowaki T (2014) Adiponectin receptors: a review of their structure, function and how they work. Best Pract Res Clin Endocrinol Metab 28(1):15–23. doi:10.1016/j.beem.2013.09.003

    Article  CAS  PubMed  Google Scholar 

  41. Tanabe H, Fujii Y, Okada-Iwabu M, Iwabu M, Nakamura Y, Hosaka T, Motoyama K, Ikeda M, Wakiyama M, Terada T, Ohsawa N, Hato M, Ogasawara S, Hino T, Murata T, Iwata S, Hirata K, Kawano Y, Yamamoto M, Kimura-Someya T, Shirouzu M, Yamauchi T, Kadowaki T, Yokoyama S (2015) Crystal structures of the human adiponectin receptors. Nature 520(7547):312–316. doi:10.1038/nature14301

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Yamaguchi N, Argueta JG, Masuhiro Y, Kagishita M, Nonaka K, Saito T, Hanazawa S, Yamashita Y (2005) Adiponectin inhibits Toll-like receptor family-induced signaling. FEBS Lett 579(30):6821–6826. doi:10.1016/j.febslet.2005.11.019

    Article  CAS  PubMed  Google Scholar 

  43. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8(11):1288–1295. doi:10.1038/nm788

    Article  CAS  PubMed  Google Scholar 

  44. Yoon MJ, Lee GY, Chung JJ, Ahn YH, Hong SH, Kim JB (2006) Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. Diabetes 55(9):2562–2570. doi:10.2337/db05-1322

    Article  CAS  PubMed  Google Scholar 

  45. Cheng KK, Lam KS, Wang Y, Huang Y, Carling D, Wu D, Wong C, Xu A (2007) Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes 56(5):1387–1394. doi:10.2337/db06-1580

    Article  PubMed  Google Scholar 

  46. Mao X, Kikani CK, Riojas RA, Langlais P, Wang L, Ramos FJ, Fang Q, Christ-Roberts CY, Hong JY, Kim RY, Liu F, Dong LQ (2006) APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol 8(5):516–523. doi:10.1038/ncb1404

    Article  CAS  PubMed  Google Scholar 

  47. Deepa SS, Dong LQ (2009) APPL1: role in adiponectin signaling and beyond. Am J Physiol Endocrinol Metab 296(1):E22–E36. doi:10.1152/ajpendo.90731.2008

    Article  CAS  PubMed  Google Scholar 

  48. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF (2004) T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA 101(28):10308–10313. doi:10.1073/pnas.0403382101

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Denzel MS, Scimia MC, Zumstein PM, Walsh K, Ruiz-Lozano P, Ranscht B (2010) T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J Clin Investig 120(12):4342–4352. doi:10.1172/JCI43464

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Motoshima H, Wu X, Mahadev K, Goldstein BJ (2004) Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun 315(2):264–271. doi:10.1016/j.bbrc.2004.01.049

    Article  CAS  PubMed  Google Scholar 

  51. Tao L, Wang Y, Gao E, Zhang H, Yuan Y, Lau WB, Chan L, Koch WJ, Ma XL (2010) Adiponectin: an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction. Circ Res 106(2):409–417. doi:10.1161/CIRCRESAHA.109.211797

    Article  CAS  PubMed  Google Scholar 

  52. Goldstein BJ, Scalia RG, Ma XL (2009) Protective vascular and myocardial effects of adiponectin. Nat Clin Pract Cardiovasc Med 6(1):27–35. doi:10.1038/ncpcardio1398

    Article  CAS  PubMed  Google Scholar 

  53. Zhu W, Cheng KK, Vanhoutte PM, Lam KS, Xu A (2008) Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci 114(5):361–374. doi:10.1042/CS20070347

    Article  CAS  PubMed  Google Scholar 

  54. Jahng JW, Turdi S, Kovacevic V, Dadson K, Li RK, Sweeney G (2015) Pressure overload-induced cardiac dysfunction in aged male adiponectin knockout mice is associated with autophagy deficiency. Endocrinology 156(7):2667–2677. doi:10.1210/en.2015-1162

    Article  CAS  PubMed  Google Scholar 

  55. Liao Y, Takashima S, Maeda N, Ouchi N, Komamura K, Shimomura I, Hori M, Matsuzawa Y, Funahashi T, Kitakaze M (2005) Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res 67(4):705–713. doi:10.1016/j.cardiores.2005.04.018

    Article  CAS  PubMed  Google Scholar 

  56. O’Shea KM, Chess DJ, Khairallah RJ, Rastogi S, Hecker PA, Sabbah HN, Walsh K, Stanley WC (2010) Effects of adiponectin deficiency on structural and metabolic remodeling in mice subjected to pressure overload. Am J Physiol Heart Circ Physiol 298(6):H1639–H1645. doi:10.1152/ajpheart.00957.2009

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  57. Shimano M, Ouchi N, Shibata R, Ohashi K, Pimentel DR, Murohara T, Walsh K (2010) Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response. J Mol Cell Cardiol 49(2):210–220. doi:10.1016/j.yjmcc.2010.02.021

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, Ohashi K, Sakai N, Shimomura I, Kobayashi H, Terasaka N, Inaba T, Funahashi T, Matsuzawa Y (2002) Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106(22):2767–2770

    Article  CAS  PubMed  Google Scholar 

  59. Kato H, Kashiwagi H, Shiraga M, Tadokoro S, Kamae T, Ujiie H, Honda S, Miyata S, Ijiri Y, Yamamoto J, Maeda N, Funahashi T, Kurata Y, Shimomura I, Tomiyama Y, Kanakura Y (2006) Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol 26(1):224–230. doi:10.1161/01.ATV.0000194076.84568.81

    Article  CAS  PubMed  Google Scholar 

  60. Kondo K, Shibata R, Unno K, Shimano M, Ishii M, Kito T, Shintani S, Walsh K, Ouchi N, Murohara T (2010) Impact of a single intracoronary administration of adiponectin on myocardial ischemia/reperfusion injury in a pig model. Circ Cardiovasc Intervent 3(2):166–173. doi:10.1161/CIRCINTERVENTIONS.109.872044

    Article  CAS  Google Scholar 

  61. Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, Funahashi T, Ouchi N, Walsh K (2005) Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 11(10):1096–1103. doi:10.1038/nm1295

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Kojima S, Kojima S, Maruyoshi H, Nagayoshi Y, Kaikita K, Sumida H, Sugiyama S, Funahashi T, Ogawa H (2011) Hypercholesterolemia and hypoadiponectinemia are associated with necrotic core-rich coronary plaque. Int J Cardiol 147(3):371–376. doi:10.1016/j.ijcard.2009.09.536

    Article  PubMed  Google Scholar 

  63. Sawada T, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, Kawamori H, Kato H, Miyoshi N, Yoshino N, Kozuki A, Hirata K (2010) Low plasma adiponectin levels are associated with presence of thin-cap fibroatheroma in men with stable coronary artery disease. Int J Cardiol 142(3):250–256. doi:10.1016/j.ijcard.2008.12.216

    Article  PubMed  Google Scholar 

  64. Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, Maeda N, Kumada M, Okamoto Y, Nagaretani H, Nishizawa H, Kishida K, Komuro R, Ouchi N, Kihara S, Nagai R, Funahashi T, Matsuzawa Y (2002) Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 277(40):37487–37491. doi:10.1074/jbc.M206083200

    Article  CAS  PubMed  Google Scholar 

  65. Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, Uchida S, Ito Y, Takakuwa K, Matsui J, Takata M, Eto K, Terauchi Y, Komeda K, Tsunoda M, Murakami K, Ohnishi Y, Naitoh T, Yamamura K, Ueyama Y, Froguel P, Kimura S, Nagai R, Kadowaki T (2003) Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278(4):2461–2468. doi:10.1074/jbc.M209033200

    Article  CAS  PubMed  Google Scholar 

  66. Xu A, Wang Y, Lam KS, Vanhoutte PM (2010) Vascular actions of adipokines molecular mechanisms and therapeutic implications. Adv Pharmacol 60:229–255. doi:10.1016/B978-0-12-385061-4.00008-8

    Article  CAS  PubMed  Google Scholar 

  67. Ohashi K, Ouchi N, Sato K, Higuchi A, Ishikawa TO, Herschman HR, Kihara S, Walsh K (2009) Adiponectin promotes revascularization of ischemic muscle through a cyclooxygenase 2-dependent mechanism. Mol Cell Biol 29(13):3487–3499. doi:10.1128/MCB.00126-09

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Joshi MB, Philippova M, Ivanov D, Allenspach R, Erne P, Resink TJ (2005) T-cadherin protects endothelial cells from oxidative stress-induced apoptosis. FASEB J 19(12):1737–1739. doi:10.1096/fj.05-3834fje

    CAS  PubMed  Google Scholar 

  69. George J, Patal S, Wexler D, Sharabi Y, Peleg E, Kamari Y, Grossman E, Sheps D, Keren G, Roth A (2006) Circulating adiponectin concentrations in patients with congestive heart failure. Heart 92(10):1420–1424. doi:10.1136/hrt.2005.083345

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Hopkins TA, Ouchi N, Shibata R, Walsh K (2007) Adiponectin actions in the cardiovascular system. Cardiovasc Res 74(1):11–18. doi:10.1016/j.cardiores.2006.10.009

    Article  CAS  PubMed  Google Scholar 

  71. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, Hildebrandt P (2005) Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 112(12):1756–1762. doi:10.1161/CIRCULATIONAHA.104.530972

    Article  CAS  PubMed  Google Scholar 

  72. Tsutamoto T, Tanaka T, Sakai H, Ishikawa C, Fujii M, Yamamoto T, Horie M (2007) Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J 28(14):1723–1730. doi:10.1093/eurheartj/ehm154

    Article  PubMed  Google Scholar 

  73. Norrelund H, Wiggers H, Halbirk M, Frystyk J, Flyvbjerg A, Botker HE, Schmitz O, Jorgensen JO, Christiansen JS, Moller N (2006) Abnormalities of whole body protein turnover, muscle metabolism and levels of metabolic hormones in patients with chronic heart failure. J Intern Med 260(1):11–21. doi:10.1111/j.1365-2796.2006.01663.x

    Article  CAS  PubMed  Google Scholar 

  74. Van Berendoncks AM, Garnier A, Beckers P, Hoymans VY, Possemiers N, Fortin D, Martinet W, Van Hoof V, Vrints CJ, Ventura-Clapier R, Conraads VM (2010) Functional adiponectin resistance at the level of the skeletal muscle in mild to moderate chronic heart failure. Circ Heart Fail 3(2):185–194. doi:10.1161/CIRCHEARTFAILURE.109.885525

    Article  PubMed  CAS  Google Scholar 

  75. Beatty AL, Zhang MH, Ku IA, Na B, Schiller NB, Whooley MA (2012) Adiponectin is associated with increased mortality and heart failure in patients with stable ischemic heart disease: data from the Heart and Soul Study. Atherosclerosis 220(2):587–592. doi:10.1016/j.atherosclerosis.2011.11.038

    Article  CAS  PubMed  Google Scholar 

  76. Baldasseroni S, Mannucci E, Orso F, Di Serio C, Pratesi A, Bartoli N, Marella GA, Colombi C, Foschini A, Valoti P, Mossello E, Fumagalli S, Marchionni N, Tarantini F (2012) Adiponectin in outpatients with coronary artery disease: independent predictors and relationship with heart failure. Nutr Metab Cardiovasc Dis 22(3):292–299. doi:10.1016/j.numecd.2011.03.012

    Article  CAS  PubMed  Google Scholar 

  77. Ohara T, Hashimura K, Asakura M, Ogai A, Amaki M, Hasegawa T, Kanzaki H, Sonoda M, Nishizawa H, Funahashi T, Kitakaze M (2011) Dynamic changes in plasma total and high molecular weight adiponectin levels in acute heart failure. J Cardiol 58(2):181–190. doi:10.1016/j.jjcc.2011.06.010

    Article  PubMed  Google Scholar 

  78. Gustafsson S, Lind L, Zethelius B, Venge P, Flyvbjerg A, Soderberg S, Ingelsson E (2010) Adiponectin and cardiac geometry and function in elderly: results from two community-based cohort studies. Eur J Endocrinol 162(3):543–550. doi:10.1530/EJE-09-1006

    Article  CAS  PubMed  Google Scholar 

  79. Kung T, Szabo T, Springer J, Doehner W, Anker SD, von Haehling S (2011) Cachexia in heart disease: highlights from the ESC 2010. J Cachexia Sarcopenia Muscle 2(1):63–69. doi:10.1007/s13539-011-0020-z

    Article  PubMed  PubMed Central  Google Scholar 

  80. Lee Y, Kim BK, Lim YH, Kim MK, Choi BY, Shin J (2013) The relationship between adiponectin and left ventricular mass index varies with the risk of left ventricular hypertrophy. PLoS ONE 8(7):e70246. doi:10.1371/journal.pone.0070246

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Sam F, Walsh K (2010) What can adiponectin say about left ventricular function? Heart 96(5):331–332. doi:10.1136/hrt.2009.178590

    Article  PubMed  Google Scholar 

  82. Ebert T, Fasshauer M (2011) Adiponectin: sometimes good, sometimes bad? Cardiology 118(4):236–237. doi:10.1159/000329647

    Article  PubMed  Google Scholar 

  83. Sente T, Van Berendoncks AM, Hoymans VY, Vrints CJ (2015) Adiponectin resistance in skeletal muscle: pathophysiological implications in chronic heart failure. J Cachexia Sarcopenia Muscle. doi:10.1002/jcsm.12086

    PubMed  PubMed Central  Google Scholar 

  84. Hashimoto N, Kanda J, Nakamura T, Horie A, Kurosawa H, Hashimoto T, Sato K, Kushida S, Suzuki M, Yano S, Iwai R, Takahashi H, Yoshida S (2006) Association of hypoadiponectinemia in men with early onset of coronary heart disease and multiple coronary artery stenoses. Metab, Clin Exp 55(12):1653–1657. doi:10.1016/j.metabol.2006.08.005

    Article  CAS  Google Scholar 

  85. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K, Fu Y, Motone M, Yamamoto K, Matsuo A, Ohashi K, Kihara S, Funahashi T, Rakugi H, Matsuzawa Y, Ogihara T (2004) Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 43(6):1318–1323. doi:10.1161/01.HYP.0000129281.03801.4b

    Article  CAS  PubMed  Google Scholar 

  86. Lindberg S, Pedersen SH, Mogelvang R, Bjerre M, Frystyk J, Flyvbjerg A, Galatius S, Jensen JS (2012) Usefulness of adiponectin as a predictor of all cause mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol 109(4):492–496. doi:10.1016/j.amjcard.2011.09.041

    Article  CAS  PubMed  Google Scholar 

  87. Won H, Kang SM, Shin MJ, Oh J, Hong N, Park S, Lee SH, Jang Y, Chung N (2012) Plasma adiponectin concentration and its association with metabolic syndrome in patients with heart failure. Yonsei Med J 53(1):91–98. doi:10.3349/ymj.2012.53.1.91

    Article  CAS  PubMed  Google Scholar 

  88. Li S, Shin HJ, Ding EL, van Dam RM (2009) Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 302(2):179–188. doi:10.1001/jama.2009.976

    Article  CAS  PubMed  Google Scholar 

  89. Okamoto H (2009) Can adiponectin be a novel metabolic biomarker for heart failure? Circ J 73(6):1012–1013

    Article  CAS  PubMed  Google Scholar 

  90. Yamaji M, Tsutamoto T, Tanaka T, Kawahara C, Nishiyama K, Yamamoto T, Fujii M, Horie M (2009) Effect of carvedilol on plasma adiponectin concentration in patients with chronic heart failure. Circ J 73(6):1067–1073

    Article  CAS  PubMed  Google Scholar 

  91. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291(14):1730–1737. doi:10.1001/jama.291.14.1730

    Article  CAS  PubMed  Google Scholar 

  92. Kawano T, Saito T, Yasu T, Saito T, Nakamura T, Namai K, Tamemoto H, Kawakami M, Saito M, Ishikawa SE (2005) Close association of hypoadiponectinemia with arteriosclerosis obliterans and ischemic heart disease. Metab, Clin Exp 54(5):653–656. doi:10.1016/j.metabol.2004.12.009

    Article  CAS  Google Scholar 

  93. Djousse L, Wilk JB, Hanson NQ, Glynn RJ, Tsai MY, Gaziano JM (2013) Association between adiponectin and heart failure risk in the physicians’ health study. Obesity 21(4):831–834. doi:10.1002/oby.20260

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Shibata R, Izumiya Y, Sato K, Papanicolaou K, Kihara S, Colucci WS, Sam F, Ouchi N, Walsh K (2007) Adiponectin protects against the development of systolic dysfunction following myocardial infarction. J Mol Cell Cardiol 42(6):1065–1074. doi:10.1016/j.yjmcc.2007.03.808

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Kizer JR, Arnold AM, Jenny NS, Cushman M, Strotmeyer ES, Ives DG, Ding J, Kritchevsky SB, Chaves PH, Hirsch CH, Newman AB (2011) Longitudinal changes in adiponectin and inflammatory markers and relation to survival in the oldest old: the Cardiovascular Health Study All Stars study. J Gerontol A Biol Sci Med Sci 66(10):1100–1107. doi:10.1093/gerona/glr098

    Article  PubMed  CAS  Google Scholar 

  96. Kizer JR, Benkeser D, Arnold AM, Mukamal KJ, Ix JH, Zieman SJ, Siscovick DS, Tracy RP, Mantzoros CS, Defilippi CR, Newman AB, Djousse L (2012) Associations of total and high-molecular-weight adiponectin with all-cause and cardiovascular mortality in older persons: the Cardiovascular Health Study. Circulation 126(25):2951–2961. doi:10.1161/CIRCULATIONAHA.112.135202

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Macheret F, Bartz TM, Djousse L, Ix JH, Mukamal KJ, Zieman SJ, Siscovick DS, Tracy RP, Heckbert SR, Psaty BM, Kizer JR (2015) Higher circulating adiponectin levels are associated with increased risk of atrial fibrillation in older adults. Heart 101(17):1368–1374. doi:10.1136/heartjnl-2014-307015

    Article  CAS  PubMed  Google Scholar 

  98. Kizer JR, Arnold AM, Benkeser D, Ix JH, Djousse L, Zieman SJ, Barzilay JI, Tracy RP, Mantzoros CS, Siscovick DS, Mukamal KJ (2012) Total and high-molecular-weight adiponectin and risk of incident diabetes in older people. Diabetes Care 35(2):415–423. doi:10.2337/dc11-1519

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Park M, Sweeney G (2013) Direct effects of adipokines on the heart: focus on adiponectin. Heart Fail Rev 18(5):631–644. doi:10.1007/s10741-012-9337-8

    Article  CAS  PubMed  Google Scholar 

  100. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y (1999) Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100(25):2473–2476

    Article  CAS  PubMed  Google Scholar 

  101. Pineiro R, Iglesias MJ, Gallego R, Raghay K, Eiras S, Rubio J, Dieguez C, Gualillo O, Gonzalez-Juanatey JR, Lago F (2005) Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett 579(23):5163–5169. doi:10.1016/j.febslet.2005.07.098

    Article  CAS  PubMed  Google Scholar 

  102. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y (2000) Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96(5):1723–1732

    CAS  PubMed  Google Scholar 

  103. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y (2003) Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107(5):671–674

    Article  CAS  PubMed  Google Scholar 

  104. Devaraj S, Torok N, Dasu MR, Samols D, Jialal I (2008) Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop. Arterioscler Thromb Vasc Biol 28(7):1368–1374. doi:10.1161/ATVBAHA.108.163303

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, Davis KE, Bikman BT, Halberg N, Rutkowski JM, Wade MR, Tenorio VM, Kuo MS, Brozinick JT, Zhang BB, Birnbaum MJ, Summers SA, Scherer PE (2011) Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 17(1):55–63. doi:10.1038/nm.2277

    Article  CAS  PubMed  Google Scholar 

  106. Essick EE, Wilson RM, Pimentel DR, Shimano M, Baid S, Ouchi N, Sam F (2013) Adiponectin modulates oxidative stress-induced autophagy in cardiomyocytes. PLoS ONE 8(7):e68697. doi:10.1371/journal.pone.0068697

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Park M, Youn B, Zheng XL, Wu D, Xu A, Sweeney G (2011) Globular adiponectin, acting via AdipoR1/APPL1, protects H9c2 cells from hypoxia/reoxygenation-induced apoptosis. PLoS ONE 6(4):e19143. doi:10.1371/journal.pone.0019143

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Tsatsanis C, Zacharioudaki V, Androulidaki A, Dermitzaki E, Charalampopoulos I, Minas V, Gravanis A, Margioris AN (2005) Adiponectin induces TNF-alpha and IL-6 in macrophages and promotes tolerance to itself and other pro-inflammatory stimuli. Biochem Biophys Res Commun 335(4):1254–1263. doi:10.1016/j.bbrc.2005.07.197

    Article  CAS  PubMed  Google Scholar 

  109. Savill J, Dransfield I, Gregory C, Haslett C (2002) A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2(12):965–975. doi:10.1038/nri957

    Article  CAS  PubMed  Google Scholar 

  110. Takemura Y, Ouchi N, Shibata R, Aprahamian T, Kirber MT, Summer RS, Kihara S, Walsh K (2007) Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J Clin Investig 117(2):375–386. doi:10.1172/JCI29709

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Fantuzzi G (2008) Adiponectin and inflammation: consensus and controversy. J Allergy Clin Immunol 121(2):326–330. doi:10.1016/j.jaci.2007.10.018

    Article  CAS  PubMed  Google Scholar 

  112. Tomizawa A, Hattori Y, Kasai K (2009) Induction of gene expression in response to globular adiponectin in vascular endothelial cells. Life Sci 85(11–12):457–461. doi:10.1016/j.lfs.2009.07.012

    Article  CAS  PubMed  Google Scholar 

  113. Ehling A, Schaffler A, Herfarth H, Tarner IH, Anders S, Distler O, Paul G, Distler J, Gay S, Scholmerich J, Neumann E, Muller-Ladner U (2006) The potential of adiponectin in driving arthritis. J Immunol 176(7):4468–4478

    Article  CAS  PubMed  Google Scholar 

  114. Heliovaara MK, Teppo AM, Karonen SL, Tuominen JA, Ebeling P (2006) Improved glycaemia in type 1 diabetes results in decreased levels of soluble adhesion molecules with no change in serum adiponectin or most acute phase proteins. Exp Clin Endocrinol Diabetes 114(6):295–300. doi:10.1055/s-2006-924265

    Article  CAS  PubMed  Google Scholar 

  115. Kirdar S, Serter M, Ceylan E, Sener AG, Kavak T, Karadag F (2009) Adiponectin as a biomarker of systemic inflammatory response in smoker patients with stable and exacerbation phases of chronic obstructive pulmonary disease. Scand J Clin Lab Invest 69(2):219–224. doi:10.1080/00365510802474400

    Article  CAS  PubMed  Google Scholar 

  116. Miller M, Pham A, Cho JY, Rosenthal P, Broide DH (2010) Adiponectin-deficient mice are protected against tobacco-induced inflammation and increased emphysema. Am J Physiol Lung Cell Mol Physiol 299(6):L834–L842. doi:10.1152/ajplung.00326.2009

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Ho YL, Lin YH, Lee CM, Hsu RB, Ting HT, Chou NK, Chao CL, Wang SS, Hsu HC, Chen MF (2009) Prognostic significance of adipocytokines and extracellular matrix activity in heart failure patients with high B-type natriuretic peptide. Clin Biochem 42(13–14):1407–1412. doi:10.1016/j.clinbiochem.2009.06.013

    Article  CAS  PubMed  Google Scholar 

  118. Cheng X, Folco EJ, Shimizu K, Libby P (2012) Adiponectin induces pro-inflammatory programs in human macrophages and CD4+ T cells. J Biol Chem 287(44):36896–36904. doi:10.1074/jbc.M112.409516

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Park PH, McMullen MR, Huang H, Thakur V, Nagy LE (2007) Short-term treatment of RAW264.7 macrophages with adiponectin increases tumor necrosis factor-alpha (TNF-alpha) expression via ERK1/2 activation and Egr-1 expression: role of TNF-alpha in adiponectin-stimulated interleukin-10 production. J Biol Chem 282(30):21695–21703. doi:10.1074/jbc.M701419200

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Cavusoglu E, Chopra V, Battala V, Ruwende C, Yanamadala S, Eng C, Pinsky DJ, Marmur JD (2008) Baseline plasma adiponectin levels as a predictor of left ventricular systolic dysfunction in patients referred for coronary angiography. Am J Cardiol 101(8):1073–1078. doi:10.1016/j.amjcard.2007.12.008

    Article  CAS  PubMed  Google Scholar 

  121. Celik T, Yaman H (2010) Elevated adiponectin levels in patients with chronic heart failure: an independent predictor of mortality or a marker of cardiac cachexia? Int J Cardiol 144(2):319–320. doi:10.1016/j.ijcard.2009.03.006

    Article  PubMed  Google Scholar 

  122. Dieplinger B, Gegenhuber A, Poelz W, Haltmayer M, Mueller T (2009) Prognostic value of increased adiponectin plasma concentrations in patients with acute destabilized heart failure. Clin Biochem 42(10–11):1190–1193. doi:10.1016/j.clinbiochem.2009.02.023

    Article  CAS  PubMed  Google Scholar 

  123. Adamopoulos S, Coats AJ, Brunotte F, Arnolda L, Meyer T, Thompson CH, Dunn JF, Stratton J, Kemp GJ, Radda GK et al (1993) Physical training improves skeletal muscle metabolism in patients with chronic heart failure. J Am Coll Cardiol 21(5):1101–1106

    Article  CAS  PubMed  Google Scholar 

  124. Van Berendoncks AM, Beckers P, Hoymans VY, Possemiers N, Coenen S, Elseviers MM, Vrints CJ, Conraads VM (2011) beta-blockers modify the prognostic value of adiponectin in chronic heart failure. Int J Cardiol 150(3):296–300. doi:10.1016/j.ijcard.2010.04.039

    Article  PubMed  Google Scholar 

  125. Isobe T, Saitoh S, Takagi S, Takeuchi H, Chiba Y, Katoh N, Shimamoto K (2005) Influence of gender, age and renal function on plasma adiponectin level: the Tanno and Sobetsu study. Eur J Endocrinol 153(1):91–98. doi:10.1530/eje.1.01930

    Article  CAS  PubMed  Google Scholar 

  126. Van Berendoncks AM, Garnier A, Beckers P, Hoymans VY, Possemiers N, Fortin D, Van Hoof V, Dewilde S, Vrints CJ, Ventura-Clapier R, Conraads VM (2011) Exercise training reverses adiponectin resistance in skeletal muscle of patients with chronic heart failure. Heart 97(17):1403–1409. doi:10.1136/hrt.2011.226373

    Article  PubMed  CAS  Google Scholar 

  127. Dieplinger B, Gegenhuber A, Haltmayer M, Mueller T (2009) Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath. Heart 95(18):1508–1513. doi:10.1136/hrt.2009.170696

    Article  CAS  PubMed  Google Scholar 

  128. Fu M, Zhou J, Qian J, Jin X, Zhu H, Zhong C, Fu M, Zou Y, Ge J (2012) Adiponectin through its biphasic serum level is a useful biomarker during transition from diastolic dysfunction to systolic dysfunction—an experimental study. Lipids Health Dis 11:106. doi:10.1186/1476-511X-11-106

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Risch L, Saely C, Hoefle G, Rein P, Langer P, Gouya G, Marte T, Aczel S, Drexel H (2007) Relationship between glomerular filtration rate and the adipokines adiponectin, resistin and leptin in coronary patients with predominantly normal or mildly impaired renal function. Clin Chim Acta 376(1–2):108–113. doi:10.1016/j.cca.2006.07.026

    Article  CAS  PubMed  Google Scholar 

  130. Tentolouris N, Doulgerakis D, Moyssakis I, Kyriaki D, Makrilakis K, Kosmadakis G, Stamatiadis D, Katsilambros N, Stathakis C (2004) Plasma adiponectin concentrations in patients with chronic renal failure: relationship with metabolic risk factors and ischemic heart disease. Horm Metab Res 36(10):721–727. doi:10.1055/s-2004-826022

    Article  CAS  PubMed  Google Scholar 

  131. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y (2002) Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13(1):134–141

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by a doctoral Grant from the University of Antwerp and the Belgian public utility foundation VOCATIO.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tahnee Sente.

Ethics declarations

Conflict of interest

The authors declare that there are no financial or other relations that could lead to a conflict of interest regarding the publication of this paper.

Author disclosures

TS and VYH were involved in design and drafting of the manuscript. TS, AMVB, AG, CJV and VYH critically revised the manuscript. TS and VYH edited the revised version. All authors approved the final manuscript.

Ethical standards

The study was approved by the local Ethics Committee of the Antwerp University Hospital (committee for medical ethics UZA–UAntwerp) and is in keeping with the principles of the Declaration of Helsinki. All participants provided written informed consent before enrollment.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sente, T., Gevaert, A., Van Berendoncks, A. et al. The evolving role of adiponectin as an additive biomarker in HFrEF. Heart Fail Rev 21, 753–769 (2016). https://doi.org/10.1007/s10741-016-9578-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10741-016-9578-z

Keywords

Navigation